Childhood Rhabdomyosarcoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (09/28/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment of Previously Untreated Childhood Rhabdomyosarcoma

Revised text to state that the high frequency of nodal involvement and the prognostic association between nodal involvement and poorer outcome suggest that nodal sampling is appropriate. The current recommendation is to sample the regional lymph nodes.

Treatment of Recurrent Childhood Rhabdomyosarcoma

Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation for recurrent rhabdomyosarcoma.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Recurrent Childhood Rhabdomyosarcoma

Next section >
About This PDQ Summary